Pre-Open Stock Movers:

Antares Pharma, Inc. (NASDAQ: ATRS) 49% HIGHER; Halozyme Therapeutics, Inc. (NASDAQ: HALO) agreed to acquire the company for $5.60 per share in cash, or $960 million.

Sierra Oncology, Inc (Nasdaq: SRRA) 38% HIGHER; GlaxoSmithKline plc (NYSE: GSK) will acquire the company for $55 per share, or $1.9 billion.

NanoString Technologies, Inc. (NASDAQ: NSTG) 33% LOWER; announced preliminary total product and service revenue of approximately $31 million for the first quarter, versus prior guidance of $34-$38 million.

Statera Biopharma, Inc. (Nasdaq: STAB) 18% HIGHER; Enters deal with Coeptis Therapeutics to sell rights to toll-like receptor 5 (TLR5) agonist platform.

Liquidia Corporation (NASDAQ: LQDA) 13% LOWER; priced 9,803,922 share offering at $5.10.

BriaCell Therapeutics (NASDAQ: BCTX) 13% HIGHER; FDA granted Fast Track status to lead candidate, Bria-IMT;

Hillman Solutions Corp. (Nasdaq: HLMN) 11% LOWER; priced upsized 13,000,000 share secondary offering at $10.

Canoo Inc. (Nasdaq: GOEV) 8% HIGHER; selected by NASA to deliver multiple customized all-electric LV models to NASA by June 2023.

Bed Bath & Beyond (NASDAQ: BBBY) 8% LOWER; reported Q4 EPS of ($0.92), $0.95 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $2.05 billion versus the consensus estimate of $2.07 billion.

VerifyMe, Inc. (NASDAQ: VRME) 7% LOWER; entered into a securities purchase agreement with certain accredited investors to purchase approximately $5.0 million of its common stock.

Delta Air Lines (NYSE: DAL) 5% HIGHER; reported Q1 loss per share $1.23, versus the analyst estimate of -$1.27. Revenue for the quarter came in at $9.3 billion versus the consensus estimate of $8.92 billion.

PayPal Holdings, Inc. (NASDAQ: PYPL) 5% LOWER; CFO John Rainey leaves to join Walmart (NYSE: WMT).

Cardiff Oncology, Inc. (Nasdaq: CRDF) 4% LOWER; chief medical officer Katherine L. Ruffner, M.D. is leaving to pursue a new opportunity.

Affimed N.V. (Nasdaq: AFMD) 3% HIGHER; priced 22,500,000 share offering at $4.

JPMorgan (NYSE: JPM) 3% LOWER; posted Q1 EPS of $2.63,versus the consensus of $2.69. Revenue for the quarter came in at $30.7 billion versus the consensus estimate of $30.86 billion.